Fluticasone Propionate/Salmeterol xinafoate

Tier B — Position early

GSK

Originator

1998

First approval

Expiry (public)

$8.28B ▲

Peak sales

Small molecule

Type

Targets：ADRB2, GR, PLA2G4A

Brand：Airexar Spiromax, Anasma Accuhaler, Viani, Inaladuo, Seretide/Advair, Advair Diskus, Salmex, Seretide Accuhaler, Plusvent Accuhaler, Seretide MDI, Adoair Diskus, Advair HFA, Seretide Diskus, Seretide Evohaler, Adoair Aerosol, Atmadisc, Adoair, Seretide

Indications (approved)：Chronic obstructive pulmonary disease, Asthma

Regional status

Approved

2000-08-24

Approved

1998-09-01

China

Approved

2001-11-07

Japan

Approved

2007-04-18

Factories producing this API10

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

10 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Fluticasone Propionate/Salmeterol xinafoate?

Approved indications include: Chronic obstructive pulmonary disease, Asthma.

When does the Fluticasone Propionate/Salmeterol xinafoate patent expire?

No public expiry year is available for Fluticasone Propionate/Salmeterol xinafoate yet; this page updates once verified.

How do I get a quote for Fluticasone Propionate/Salmeterol xinafoate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27